Isoflux webinar: Accurate liquid biopsy approach reveals mutations in lung cancer patients

Here, Zanetti describe the application of the ERASE-Seq (Elimination of Recurrent Artifacts and Stochastic Errors) sequencing and analysis pipeline to cfDNA isolated from peripheral blood obtained from 348 lung cancer patients. ERASE-Seq leverages technical sequencing replicates and a background-aware, error-identification approach to confidently identify low-frequency variation from cfDNA datasets using amplicon panels without unique molecular identifiers (UMIs, or molecular barcodes). To assess performance, we compare results to droplet digital PCR (ddPCR), and orthogonal approach commonly used to identify low-frequency variation. We demonstrate the clinical utility of the ERASE-Seq approach in accurately detecting actionable mutations from cfDNA samples from lung cancer patients. Additionally, we identify low-frequency CH-associated mutations that could be associated with the onset of future cancers, providing promising results for ERASE-Seq's utility in future diagnostic assay development.

Thu, Apr 30, 2020 7:00 PM - 8:00 PM CEST
Dr. Cristian Ionescu Zanetti, CTO, Fluxion Biosciences inc.

Register now!